Trial reportArchives of ophthalmology (Chicago, Ill. : 1960)2009
Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation.
Trial report in Archives of ophthalmology (Chicago, Ill. : 1960), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00367133 (A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema), which is not on this map. Cited by 34 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema
Who cites it
34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Intravitreal steroids for macular edema in diabetes.The Cochrane database of systematic reviews · 2020Pooled it
- Diabetic retinopathy (treatment).BMJ clinical evidence · 2011Pooled it
- Disease-modifying effects of ranibizumab for central retinal vein occlusion.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2022Trial
- Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial.JAMA ophthalmology · 2013Trial
- Comparative study of vitrectomy versus intravitreous triamcinolone for diabetic macular edema on randomized paired-eyes.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2012Trial
- Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation.Retina (Philadelphia, Pa.) · 2011Trial
- INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study: Baseline Analysis of 24 Aqueous Cytokines.Ophthalmology science · 2026Article
- Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate.Biomedicines · 2023Review
- Amine oxidase copper-containing 3 (AOC3) inhibition: a potential novel target for the management of diabetic retinopathy.International journal of retina and vitreous · 2021Review
- Efficacy of topical dorzolamide 2% in diabetic cystoid macular edema.International journal of ophthalmology · 2021Article
- The Evolving Treatment of Diabetic Retinopathy.Clinical ophthalmology (Auckland, N.Z.) · 2020Review
- OMICs approaches-assisted identification of macrophages-derived MIP-1γ as the therapeutic target of botanical products TNTL in diabetic retinopathy.Cell communication and signaling : CCS · 2019Article
- Corticosteroid Treatment in Diabetic Macular Edema.Turkish journal of ophthalmology · 2017Review
- Diabetic retinopathy: research to clinical practice.Clinical diabetes and endocrinology · 2017Review
- Report From the NEI/FDA Diabetic Retinopathy Clinical Trial Design and Endpoints Workshop.Investigative ophthalmology & visual science · 2016Review
- New Diagnostic and Therapeutic Approaches for Preventing the Progression of Diabetic Retinopathy.Journal of diabetes research · 2016Review
- Effect of focal laser photocoagulation in eyes with mild to moderate non-proliferative diabetic retinopathy.International journal of ophthalmology · 2016Article
- Advances in the management of diabetic macular oedema based on evidence from the Diabetic Retinopathy Clinical Research Network.Singapore medical journal · 2015Review
- A novel intravitreal fluocinolone acetonide implant (Iluvien(®)) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series.Clinical ophthalmology (Auckland, N.Z.) · 2015Article
- Ranibizumab for Visual Impairment due to Diabetic Macular Edema: Real-World Evidence in the Italian Population (PRIDE Study).Journal of ophthalmology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo compare the effect of intravitreal triamcinolone acetonide with focal/grid photocoagulation on the progression of diabetic retinopathy.
methodsWe performed an exploratory analysis of participants with diabetic macular edema randomly assigned to receive laser therapy or intravitreal triamcinolone acetonide (1 or 4 mg). Fundus photographs were obtained at baseline and 1, 2, and 3 years. The main outcome measure was progression to proliferative diabetic retinopathy or worsening of 2 or more severity levels on reading-center masked assessment of 7-field fundus photographs, plus additional eyes that received panretinal photocoagulation or had a vitreous hemorrhage.
resultsFrom July 15, 2004, through May 5, 2006, 840 eyes from 693 participants were enrolled in the study and randomly assigned to receive laser therapy (n = 330), 1 mg of triamcinolone acetonide (n = 256), or 4 mg of triamcinolone acetonide (n = 254). The cumulative probability of progression of retinopathy at 2 years was 31% (laser group), 29% (1-mg group), and 21% (4-mg group) (P = .64 in the 1-mg group and .005 in the 4-mg group compared with the laser group). These differences appeared to be sustained at 3 years.
conclusionsIntravitreal triamcinolone acetonide (4 mg) appeared to reduce the risk of progression of diabetic retinopathy. Given the exploratory nature of this analysis and because intravitreal triamcinolone adverse effects include cataract formation and glaucoma, use of this treatment merely to reduce the rates of progression of proliferative diabetic retinopathy or worsening of the level of diabetic retinopathy does not seem warranted at this time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.